Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

SELLAS Life Sciences Gr Q4 EPS $(0.25) Misses $(0.21) Estimate

Author: Benzinga Newsdesk | March 28, 2024 11:35pm
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 41.86 percent increase over losses of $(0.43) per share from the same period last year.

Posted In: SLS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist